Insulet (NSDQ:PODD) said this week that it inked a deal with Samsung to develop an Omnipod insulin delivery system that would allow users to control their insulin pump therapy with a Galaxy smartphone.
If approved, the system would be the first of its kind, according to the Billerica, Mass.-based company.
All Samsung mobile devices are built with the Samsung Knox mobile security platform, according to Insulet, which will complement the security features provided by Insulet’s FDA-cleared Omnipod Dash mobile app.
“Over the last few years, there have been many exciting advancements that allow individuals to experience how phone control could improve their diabetes management,” president & CEO Shacey Petrovic said in prepared remarks. “For us, because we are delivering a life-sustaining drug, it’s critical that we have the highest measures of safety and security in place. We are thrilled to work with Samsung, the global leader in smartphones, to lead the way in offering phone control of an insulin pump in a way that is simple, safe and secure.”
“By integrating Samsung smartphones with drug delivery medical devices like Insulet’s Omnipod System, we’ve demonstrated that consumer-based digital health technologies can not only monitor and track one’s condition, but they can enable patient control of medical treatments,” CMO & VP/GM for Samsung’s enterprise healthcare division, Dr. David Rhew, added. “As chronic conditions like diabetes continue to increase in prevalence across all demographics, integrated partnerships between consumer technology and medical device companies, with support from regulators, will help establish a new paradigm of consumerism in healthcare in which medical care adapts to consumer lifestyle and preference.”
